Identification of novel formyl peptide receptor-like 1 agonists that induce macrophage tumor necrosis factor α production

Igor A. Schepetkin, Liliya N. Kirpotina, Jun Tian, Andrey Ivanovich Khlebnikov, Richard D. Ye, Mark T. Quinn

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Development of immunomodulatory agents that enhance innate immune responses represents a promising strategy for combating infectious diseases. In the present studies, we screened a series of 71 arylcarboxylic acid hydrazide derivatives for their ability to induce macrophage tumor necrosis factor α (TNF-α) production and identified six such compounds, including one compound previously shown to be a formyl peptide receptor (FPR/FPRL1) agonist. The two most potent compounds [compound 1, nicotinic acid [5-(3-bromophenyl)-2- furyl]methylene-hydrazide; compound 2, 4-fluoro-benzoic acid [5-(3-trifluoromethyl-phenyl)-2-furyl]-methylene-hydrazide] were selected for further analysis. These compounds induced de novo production of TNF-α in a dose-and time-dependent manner in human and murine monocyte/macrophage cell lines and in primary macrophages. These compounds also induced mobilization of intracellular Ca2+, production of reactive oxygen species, and chemotaxis in human and murine phagocytes. Induction of macrophage TNF-α production was pertussis toxin-sensitive, and analysis of the cellular target of these compounds showed that they were FPRL1-specific agonists and that this response was blocked by FPR/FPRL1 and FPRL1-specific antagonists. In addition, pharmacophore modeling showed a high degree of similarity for low-energy conformations of these two compounds to the current pharmacophore model for FPR ligands (Mol Pharmacol 68:1301-1310, 2005). Overall, these compounds represent novel FPRL1 agonists that induce TNF-α, a response distinct from those induced by other known FPR and FPRL1 agonists.

Original languageEnglish
Pages (from-to)392-402
Number of pages11
JournalMolecular Pharmacology
Volume74
Issue number2
DOIs
Publication statusPublished - Aug 2008
Externally publishedYes

Fingerprint

Formyl Peptide Receptor
Tumor Necrosis Factor-alpha
Macrophages
Aptitude
Benzoic Acid
Niacin
Pertussis Toxin
Chemotaxis
Phagocytes
Innate Immunity
Communicable Diseases
Monocytes
Reactive Oxygen Species
Ligands
Cell Line
Acids

ASJC Scopus subject areas

  • Pharmacology

Cite this

Identification of novel formyl peptide receptor-like 1 agonists that induce macrophage tumor necrosis factor α production. / Schepetkin, Igor A.; Kirpotina, Liliya N.; Tian, Jun; Khlebnikov, Andrey Ivanovich; Ye, Richard D.; Quinn, Mark T.

In: Molecular Pharmacology, Vol. 74, No. 2, 08.2008, p. 392-402.

Research output: Contribution to journalArticle

@article{a4021c806eeb4613ad161250d34fd7d5,
title = "Identification of novel formyl peptide receptor-like 1 agonists that induce macrophage tumor necrosis factor α production",
abstract = "Development of immunomodulatory agents that enhance innate immune responses represents a promising strategy for combating infectious diseases. In the present studies, we screened a series of 71 arylcarboxylic acid hydrazide derivatives for their ability to induce macrophage tumor necrosis factor α (TNF-α) production and identified six such compounds, including one compound previously shown to be a formyl peptide receptor (FPR/FPRL1) agonist. The two most potent compounds [compound 1, nicotinic acid [5-(3-bromophenyl)-2- furyl]methylene-hydrazide; compound 2, 4-fluoro-benzoic acid [5-(3-trifluoromethyl-phenyl)-2-furyl]-methylene-hydrazide] were selected for further analysis. These compounds induced de novo production of TNF-α in a dose-and time-dependent manner in human and murine monocyte/macrophage cell lines and in primary macrophages. These compounds also induced mobilization of intracellular Ca2+, production of reactive oxygen species, and chemotaxis in human and murine phagocytes. Induction of macrophage TNF-α production was pertussis toxin-sensitive, and analysis of the cellular target of these compounds showed that they were FPRL1-specific agonists and that this response was blocked by FPR/FPRL1 and FPRL1-specific antagonists. In addition, pharmacophore modeling showed a high degree of similarity for low-energy conformations of these two compounds to the current pharmacophore model for FPR ligands (Mol Pharmacol 68:1301-1310, 2005). Overall, these compounds represent novel FPRL1 agonists that induce TNF-α, a response distinct from those induced by other known FPR and FPRL1 agonists.",
author = "Schepetkin, {Igor A.} and Kirpotina, {Liliya N.} and Jun Tian and Khlebnikov, {Andrey Ivanovich} and Ye, {Richard D.} and Quinn, {Mark T.}",
year = "2008",
month = "8",
doi = "10.1124/mol.108.046946",
language = "English",
volume = "74",
pages = "392--402",
journal = "Molecular Pharmacology",
issn = "0026-895X",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "2",

}

TY - JOUR

T1 - Identification of novel formyl peptide receptor-like 1 agonists that induce macrophage tumor necrosis factor α production

AU - Schepetkin, Igor A.

AU - Kirpotina, Liliya N.

AU - Tian, Jun

AU - Khlebnikov, Andrey Ivanovich

AU - Ye, Richard D.

AU - Quinn, Mark T.

PY - 2008/8

Y1 - 2008/8

N2 - Development of immunomodulatory agents that enhance innate immune responses represents a promising strategy for combating infectious diseases. In the present studies, we screened a series of 71 arylcarboxylic acid hydrazide derivatives for their ability to induce macrophage tumor necrosis factor α (TNF-α) production and identified six such compounds, including one compound previously shown to be a formyl peptide receptor (FPR/FPRL1) agonist. The two most potent compounds [compound 1, nicotinic acid [5-(3-bromophenyl)-2- furyl]methylene-hydrazide; compound 2, 4-fluoro-benzoic acid [5-(3-trifluoromethyl-phenyl)-2-furyl]-methylene-hydrazide] were selected for further analysis. These compounds induced de novo production of TNF-α in a dose-and time-dependent manner in human and murine monocyte/macrophage cell lines and in primary macrophages. These compounds also induced mobilization of intracellular Ca2+, production of reactive oxygen species, and chemotaxis in human and murine phagocytes. Induction of macrophage TNF-α production was pertussis toxin-sensitive, and analysis of the cellular target of these compounds showed that they were FPRL1-specific agonists and that this response was blocked by FPR/FPRL1 and FPRL1-specific antagonists. In addition, pharmacophore modeling showed a high degree of similarity for low-energy conformations of these two compounds to the current pharmacophore model for FPR ligands (Mol Pharmacol 68:1301-1310, 2005). Overall, these compounds represent novel FPRL1 agonists that induce TNF-α, a response distinct from those induced by other known FPR and FPRL1 agonists.

AB - Development of immunomodulatory agents that enhance innate immune responses represents a promising strategy for combating infectious diseases. In the present studies, we screened a series of 71 arylcarboxylic acid hydrazide derivatives for their ability to induce macrophage tumor necrosis factor α (TNF-α) production and identified six such compounds, including one compound previously shown to be a formyl peptide receptor (FPR/FPRL1) agonist. The two most potent compounds [compound 1, nicotinic acid [5-(3-bromophenyl)-2- furyl]methylene-hydrazide; compound 2, 4-fluoro-benzoic acid [5-(3-trifluoromethyl-phenyl)-2-furyl]-methylene-hydrazide] were selected for further analysis. These compounds induced de novo production of TNF-α in a dose-and time-dependent manner in human and murine monocyte/macrophage cell lines and in primary macrophages. These compounds also induced mobilization of intracellular Ca2+, production of reactive oxygen species, and chemotaxis in human and murine phagocytes. Induction of macrophage TNF-α production was pertussis toxin-sensitive, and analysis of the cellular target of these compounds showed that they were FPRL1-specific agonists and that this response was blocked by FPR/FPRL1 and FPRL1-specific antagonists. In addition, pharmacophore modeling showed a high degree of similarity for low-energy conformations of these two compounds to the current pharmacophore model for FPR ligands (Mol Pharmacol 68:1301-1310, 2005). Overall, these compounds represent novel FPRL1 agonists that induce TNF-α, a response distinct from those induced by other known FPR and FPRL1 agonists.

UR - http://www.scopus.com/inward/record.url?scp=47949115987&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47949115987&partnerID=8YFLogxK

U2 - 10.1124/mol.108.046946

DO - 10.1124/mol.108.046946

M3 - Article

VL - 74

SP - 392

EP - 402

JO - Molecular Pharmacology

JF - Molecular Pharmacology

SN - 0026-895X

IS - 2

ER -